Close Menu
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

November 21, 2026

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

November 21, 2026

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026
Facebook X (Twitter) Instagram
Trending
  • Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations
  • The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India
  • ‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam
  • HydraSure’s Gen Z Team Turns GTA VI Launch Day Into a Giveaway – Planned and Live in 24 Hours
  • Kingston Debuts at Embedded World India, Deepening Its B2B Push in India’s Enterprise and Industrial Markets
  • Heart and Lung Transplant Recipients Share Stories of a New Life at KIMS Patient Meet in Indore
  • Rahul Gupta: 10 Years of Selfless Service, Compassion and Humanity
  • Vijay Arora Announces Sataack 50, a Professional Tennis-Ball Cricket League for Men and Women
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World
The Startup StoryThe Startup Story
Home»Press Release»TRANSFORM II Trial Hits Enrollment Milestone: Redefining Coronary Care with Sirolimus-Coated Balloons
Press Release

TRANSFORM II Trial Hits Enrollment Milestone: Redefining Coronary Care with Sirolimus-Coated Balloons

Arjun SinghBy Arjun SinghJune 14, 2025No Comments
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

New Delhi [India], June 14: The Fondazione Ricerca e Innovazione Cardiovascolare (RIC) has successfully finished patient enrolment for TRANSFORM II, one of the most ambitious and extensive randomised controlled trials (RCTs) ever carried out in the field of cardiovascular care, at a pivotal point for the future of interventional cardiology.  In order to treat de-novo coronary artery disease, this international project is contrasting the popular everolimus-eluting stent (EES) with the innovative MagicTouch Sirolimus-Coated Balloon (SCB).

The trial, helmed by the distinguished Prof. Bernardo Cortese of the Harrington Heart & Vascular Institute (Cleveland, USA), reached its enrollment target of 1,832 patients on June 6, 2025. The culmination of more than three years of relentless dedication, TRANSFORM II spans 52 global centres across Europe, Asia, and South America, making it one of the most geographically expansive RCTs focused on drug-coated balloon technology.

A New Chapter for Coronary Intervention

The sirolimus-coated balloon has emerged as a compelling alternative to drug-eluting stents for small vessel coronary artery disease. Traditionally, stents, while life-saving, effectively cage arteries, a strategy not without long-term complications in small-diameter vessels. TRANSFORM II is rewriting this playbook.

“After 3.5 years, we’ve reached a huge milestone. This trial wasn’t just large; it was ambitious, spanning continents and medical cultures,” said Prof. Cortese. “We aim to drive the adoption of drug-coated balloons, especially sirolimus-based options, using real-world patient data and comparing them with the most established DES technology available.”

High-Stakes Science in Action

With 1,832 patients now onboard, TRANSFORM II is positioned to deliver high-impact data. The trial compares the MagicTouch SCB, a product of Concept Medical, against the gold-standard everolimus-eluting stent.

Key trial parameters include:

  • Primary Endpoint: Target Lesion Failure (TLF) at 12 months
  • Patient Population: Those with de-novo coronary lesions in vessels 2.0 mm–3.5 mm in diameter
  • Monitoring Period: Up to 60 months
  • Sub-study: Optical Coherence Tomography (OCT) in 70 patients to assess arterial healing and patency at 9 months

These results are poised to fill a critical evidence gap in the treatment of small vessel coronary artery disease.

The Global Cardiovascular Community Watches Closely

Dr. Manish Doshi, Founder & Managing Director of Concept Medical, called the enrollment milestone “a testament to international collaboration and clinical rigour.”

“We’re proud to support what may become a landmark study in cardiology,” said Dr. Doshi. “Sirolimus-coated balloon technology is not just an alternative; it could be a paradigm shift. This trial’s scale and scientific design speak volumes about our collective vision to elevate patient care.”

Concept Medical’s MagicTouch SCB is already CE Mark-approved and carries Breakthrough Device Designation from the U.S. FDA for treating both small coronary vessels and in-stent restenosis.

Why This Matters: Beyond the Numbers

Roughly 80% of patients undergoing percutaneous coronary interventions (PCI) fall into the vessel size category being studied in TRANSFORM II. In these smaller arteries, placing a metallic stent can sometimes do more harm than good in the long term. That’s where sirolimus-coated balloon technology comes into its own: it delivers the anti-restenotic drug without leaving a permanent implant.

The MagicTouch SCB uses Nanoluté™ technology, delivering sub-micron sirolimus particles into the vessel wall via a biocompatible carrier. This ensures deep penetration and drug efficacy without structural compromise.

As Prof. Cortese aptly put it: “We are paving the route for the modern angioplasty era.”

A Look Ahead

With enrollment complete, attention now turns to patient monitoring and eventual results. The 12-month outcomes will be closely watched by regulatory bodies, interventional cardiologists, and healthcare policymakers. A favourable comparison for SCBs could catalyse a major shift in global treatment protocols, offering millions of patients a safer, non-stent-based alternative.

And the momentum is building. As new ARC guidelines support broader use of drug-coated balloons, TRANSFORM II may serve as the definitive evidence base to accelerate that adoption.

Conclusion: A Trial That Could Transform

TRANSFORM II stands as more than a clinical trial; it is a vision for the future of cardiovascular care. With the sirolimus-coated balloon by Fondazione Ricerca e Innovazione Cardiovascolare now standing toe-to-toe with traditional stent therapy, the upcoming data could well revolutionise the practice of angioplasty and reframe how the medical community approaches coronary disease. As the world waits for results, one thing is clear: this trial isn’t just about numbers, it’s about redefining care, one artery at a time.

The article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.

PR press-release
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
Arjun Singh
  • Website

Related Posts

Best Crypto Presale 2026: AlphaPepe Triggers Buying Surge with Up to 200% Bonus Drop as Bitcoin Eyes $100K

September 1, 2026

Resilience Actions, a Re Sustainability Initiative, Launches ECOHUB.IN to Power India’s Climate and Circular Economy Innovation Ecosystem

July 3, 2026

Social Activist Shanaya Sharma Honored with Prestigious Nari Astitva Award 2026

March 10, 2026

Comments are closed.

Top Posts

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

November 21, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020

Make your own inhouse library and learn

February 22, 2020
Don't Miss
National

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

By Arjun SinghNovember 21, 2026

Kharagpur (West Bengal) [India], November 21: Pan IIT Alumni India has welcomed Prime Minister Narendra…

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

November 21, 2026

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026

HydraSure’s Gen Z Team Turns GTA VI Launch Day Into a Giveaway – Planned and Live in 24 Hours

November 21, 2026
Most Popular

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

November 21, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020
Categories
  • Business
  • Business News
  • Education
  • Entertainment
  • Finance
  • Health
  • Lifestyle
  • National
  • Press Release
  • Sports
  • Technology
  • Uncategorized
  • World
Our Picks

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

November 21, 2026

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

November 21, 2026

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026

Type above and press Enter to search. Press Esc to cancel.